These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2345069)

  • 41. Pharmacological activities of spirogermanium and other structurally related azaspiranes: effects on tumor cell and macrophage functions.
    Mirabelli CK; Badger AM; Sung CP; Hillegass L; Sung CM; Johnson RK; Picker D; Schwartz D; Dorman J; Martellucci S
    Anticancer Drug Des; 1989 Mar; 3(4):231-42. PubMed ID: 2930625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
    de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
    Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of spirogermanium and radiation therapy on the 9L rat brain tumor model.
    Kimler BF; Martin DF; Evans RG; Morantz RA; Vats TS
    NCI Monogr; 1988; (6):115-8. PubMed ID: 3352753
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Preliminary study on the suppression of experimental autoimmune encephalomyelitis in the Lewis rat with spirogermanium.
    Sacks HJ; Braunstein V; Brosnan CF
    J Neuropathol Exp Neurol; 1987 May; 46(3):250-61. PubMed ID: 3494106
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors: correlations with clinical characteristics and safety.
    Guo F; Letrent SP; Munster PN; Britten CD; Gelmon K; Tolcher AW; Sharma A
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):97-109. PubMed ID: 17805538
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Phase I trial of piritrexim capsules using prolonged, low-dose oral administration for the treatment of advanced malignancies.
    Feun LG; Savaraj N; Benedetto P; Hanlon J; Sridhar KS; Collier M; Richman S; Liao SH; Clendeninn NJ
    J Natl Cancer Inst; 1991 Jan; 83(1):51-5. PubMed ID: 1984518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of spirogermanium (2-aza-8-germanspiro[4.5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride) by fluorometric ion-pair extraction. Application to the uniformity of content of solutions for intravenous injection.
    Riley CM; Monnot EA; Stobaugh JF; Slavik M
    J Pharm Biomed Anal; 1989; 7(3):385-92. PubMed ID: 2488639
    [No Abstract]   [Full Text] [Related]  

  • 48. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors.
    Korfel A; Scheulen ME; Schmoll HJ; Gründel O; Harstrick A; Knoche M; Fels LM; Skorzec M; Bach F; Baumgart J; Sass G; Seeber S; Thiel E; Berdel WE
    Clin Cancer Res; 1998 Nov; 4(11):2701-8. PubMed ID: 9829732
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC).
    Rapoport B; Chua D; Poma A; Arora S; Wang Y; Fein LE
    Support Care Cancer; 2015 Nov; 23(11):3281-8. PubMed ID: 25940030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
    Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
    J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I study of recombinant interferon-beta in patients with advanced malignant disease.
    Ravandi F; Estrov Z; Kurzrock R; Breitmeyer JB; Maschek BJ; Talpaz M
    Clin Cancer Res; 1999 Dec; 5(12):3990-8. PubMed ID: 10632330
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Trypanosoma cruzi: inhibition by spirogermanium hydrochloride.
    Tanowitz HB; Brennessel DJ; Baum SG; Salgo MP; Braunstein V; Wittner M
    Exp Parasitol; 1987 Aug; 64(1):57-63. PubMed ID: 3301388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy.
    Rapoport B; Schwartzberg L; Chasen M; Powers D; Arora S; Navari R; Schnadig I
    Eur J Cancer; 2016 Apr; 57():23-30. PubMed ID: 26851398
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cytotoxic effects and biological activity of 2-aza-8-germanspiro[4,5]-decane-2-propanamine-8,8-diethyl-N,N-dimethyl dichloride (NSC 192965; spirogermanium) in vitro.
    Hill BT; Whatley SA; Bellamy AS; Jenkins LY; Whelan RD
    Cancer Res; 1982 Jul; 42(7):2852-6. PubMed ID: 7200828
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase I study of mitoxantrone on a daily X 5 schedule.
    Goldsmith MA; Ohnuma T; Jaffrey IH; Greenspan EM; Holland JF
    Am J Clin Oncol; 1984 Oct; 7(5):567-70. PubMed ID: 6507380
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties.
    Syed S; Takimoto C; Hidalgo M; Rizzo J; Kuhn JG; Hammond LA; Schwartz G; Tolcher A; Patnaik A; Eckhardt SG; Rowinsky EK
    Clin Cancer Res; 2004 Oct; 10(19):6512-21. PubMed ID: 15475438
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer.
    Dragovich T; Mendelson D; Kurtin S; Richardson K; Von Hoff D; Hoos A
    Cancer Chemother Pharmacol; 2006 Dec; 58(6):759-64. PubMed ID: 16847673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.